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Abstract
Background: Abnormal cell migration and invasion underlie metastasis, and actomyosin contractility is a key regulator of 
tumor invasion. The links between cancer migratory behavior and DNA damage are poorly understood.
Methods: Using 3D collagen systems to recapitulate melanoma extracellular matrix, we analyzed the relationship between 
the actomyosin cytoskeleton of migrating cells and DNA damage. We used multiple melanoma cell lines and microarray 
analysis to study changes in gene expression and in vivo intravital imaging (n = 7 mice per condition) to understand how 
DNA damage impacts invasive behavior. We used Protein Tissue Microarrays (n = 164 melanomas) and patient databases 
(n = 354 melanoma samples) to investigate the associations between markers of DNA damage and actomyosin cytoskeletal 
features. Data were analyzed with Student’s and multiple t tests, Mann-Whitney’s test, one-way analysis of variance, and 
Pearson correlation. All statistical tests were two-sided.
Results: Melanoma cells with low levels of Rho-ROCK–driven actomyosin are subjected to oxidative stress-dependent DNA 
damage and ATM-mediated p53 protein stabilization. This results in a specific transcriptional signature enriched in DNA 
damage/oxidative stress responsive genes, including Tumor Protein p53 Inducible Protein 3 (TP53I3 or PIG3). PIG3, which 
functions in DNA damage repair, uses an unexpected catalytic mechanism to suppress Rho-ROCK activity and impair tumor 
invasion in vivo. This regulation was suppressed by antioxidants. Furthermore, PIG3 levels decreased while ROCK1/2 levels 
increased in human metastatic melanomas (ROCK1 vs PIG3; r = -0.2261, P < .0001; ROCK2 vs PIG3: r = -0.1381, P = .0093).
Conclusions: The results suggest using Rho-kinase inhibitors to reactivate the p53-PIG3 axis as a novel therapeutic strategy; 
we suggest that the use of antioxidants in melanoma should be very carefully evaluated.
Malignant melanoma is the most serious type of skin cancer 
because of its high metastatic ability (1–3). Cell migration is a 
key process during metastatic dissemination of cancer cells. 
Individual cells can migrate using a variety of strategies, the mes-
enchymal-”elongated” and the amoeboid-”rounded” modes being 
the extremes of the spectrum (4–6). Mesenchymal-elongated 
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migration is characterized by actin-dependent protrusions, high 
adhesion, and lower actomyosin contractility (7,8), while amoe-
boid migration is driven by high actomyosin contractility (7,8), 
blebs (9), low adhesion (7,10), and high cytokine signaling (11,12). 
The contractile cortex is important for amoeboid-rounded to 
intermediate forms of movement (5,13,14), while some degree of 
contractility is required to retract protrusions in elongated-mes-
enchymal migration (15). Therefore, the actomyosin cytoskeleton 
is key in controlling tumor dissemination.
Rho GTPase signals to ROCK1/2 to promote actomyosin by 
decreasing myosin phosphatase activity, thus increasing phos-
phorylation of myosin light chain 2 (MLC2) (16). In migrat-
ing cells, Rac and Rho GTPase signaling suppress each other 
(8,11,14,17,18). The invasive fronts of melanomas are enriched 
in rounded cells (11,12) with fast amoeboid migration predomi-
nating in those invasive fronts (8,11,14,17).
It is unclear how motile cancer cells regulate DNA damage 
and how this impacts tumor dissemination. Increased genera-
tion of reactive oxygen species (ROS) often overcomes the anti-
oxidant systems in cancer cells, resulting in oxidative stress. 
ROS act as second messenger molecules when present in low 
amounts, but at higher concentrations ROS can lead to senes-
cence or apoptosis (19). Melanocytes protect the skin from UV 
irradiation by producing melanin, which renders cells of melano-
cytic origin particularly sensitive to ROS (20). It is important to 
better understand how melanomas respond to oxidative stress.
Free radicals cause DNA damage, and the ataxia-telangiec-
tasia mutated (ATM) protein is activated following DNA dam-
age to sense double-strand breaks (21). ROS are also detected 
by p53 (22), which has an intricate relationship with oxidative 
stress (23–25). Mitochondria are a major source of intracellular 
ROS (26): however, less is known about other sources of ROS in 
cancer. Nonmitochondrial ROS are produced by NADPH oxidase, 
regulated by Rac1/3 (27–29) through binding to p67phox (30–32) 
and by 5-lipoxygenase regulated by Rac1 (33).
ROS signaling is very complex, as indicated by the failure of anti-
oxidant therapies. Clinical trials using antioxidants have resulted 
in higher cancer incidence in the treated groups (34–37), while 
some chemotherapies increase ROS and offer therapeutic oppor-
tunities (38). We explored the links between actomyosin dynamics 
driving tumor invasion and oxidative stress–induced DNA damage. 
We studied changes in gene expression and used in vivo intravital 
imaging to understand how the DNA damage response impacts 
invasive behavior. We also investigated the associations between 
markers of DNA damage and actomyosin cytoskeletal features.
Methods
Cell Culture
Human melanoma A375P and A375M2 cells were from Prof. 
Richard Hynes (HHMI, MIT, USA), and SBCL2, WM1361, Skmel23, 
WM266.4, 501MEL, and Skmel28 were from Prof. Richard Marais 
(CRUK Manchester Institute). Cells were maintained in DMEM 
(Gibco) supplemented with 10% fetal calf serum (FCS), 100 μg/mL 
streptomycin and 60 μg/mL penicillin. RPMI containing 10% FCS 
was used for WM1361 and SBCL2. Cells were kept in culture for 
a maximum of three to four passages, and cell phenotypes were 
verified in every experiment.
Animal Welfare
All mice were maintained under specific pathogen-free con-
ditions and handled in accordance with the Institutional 
Committees on Animal Welfare of the UK Home Office (The 
Home Office Animals Scientific Procedures Act, 1986). All ani-
mal experiments were carried out under licence from the Home 
Office, UK.
Tumor Xenografts and Imaging
Nude mice were injected subcutaneously with A375M2 cells 
stably expressing GFP (control = 7 or wild-type-PIG3 = 7). Tumor 
growth was monitored and measured at the indicated time 
intervals until the first mouse was used for imaging (end point). 
Tumor volume was calculated using the formula: π/6 x (w x l 
x h). When tumors reached visible size (5–9 mm in diameter), 
mice were anesthetized and imaged as described (39). For intra-
vital imaging, seven different regions were imaged simultane-
ously for two hours for each tumor (approximately 50 µm deep 
on average). Moving cells were defined as those that moved 
10  μm or more for at least 20 minutes. Immunofluorescence 
experiments in xenografts are described in the Supplementary 
Materials (available online).
Confocal Fluorescent and Time-Lapse Microscopy
Cells seeded on top of a thick layer of collagen I were fixed with 
p-formaldehyde, permeabilized with 0.3% Triton-X 100 (v/v), 
and blocked with 4% BSA in PBS for 30 minutes. Cells were then 
incubated with primary antibody (pMLC Ser19, Cell Signaling) 
and stained with secondary Alexa Fluor-647 anti-rabbit (Life 
Technologies) and Alexa Fluor 546-phalloidin for F-actin detec-
tion (Life Technologies). Multisite bright-field microscopy of 
cells in 24-well plates containing thick layers of collagen was 
performed (8). Further details are given in the Supplementary 
Materials (available online).
Immunohistochemistry
The high-density melanoma tissue microarrays (Tissue 
Microarray ME2082b and Tissue Microarray ME208) were from 
Biomax (Rockville, MD). PIG3 antigen was retrieved by pressure 
cooker using sodium citrate buffer (10 mM Sodium Citrate, pH 
6.0) for 15 minutes and detected with mouse monoclonal PIG3 
antibody (PIG3; NBP2-01301 Novus Biologicals Inc., 1:100) and 
the Liquid Permanent Red Chromogen (Dako). Hematoxylin was 
used to counterstain. Images were blind-scored for PIG3 inten-
sity as negative, low, moderate, and high. Quantification of cell 
morphology in Figure  8G was performed on hematoxylin and 
eosin (H&E) stainings. Each core sample was imaged for three 
separate fields, and 10 representative cells were scored for 
roundness index. Details on antibodies, inhibitors, plasmids, 
transfection, RNAi experiments, expression constructs, track-
ing and migration assays, manual classification of cell morphol-
ogy, quantitative real-time one step polymerase chain reaction 
(PCR), immunoblotting, pull-down assays, quantitative assay of 
SA-β-gal, intracellular measurement of ROS, Annexin V apop-
totic assay, and RNAI sequences are given in the Supplementary 
Materials (available online).
Analysis of PIG3, ROCK1, and ROCK2 Expression 
From Human Databases
Gene expression data of a total of 354 human melanoma sam-
ples from The Cancer Genome Atlas (TCGA) database (http://
cancergenome.nih.gov/) were used to analyze PIG3, ROCK1, 
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and ROCK2 expression in melanoma progression. We only took 
account patients who had not received neo-adjuvant treatment 
prior to the resection of the tumor that yielded the sample sub-
mitted for TCGA. We only considered samples with greater than 
70% tumor cell content. Normalized mRNA expression data and 
z-scores for mRNA expression data were downloaded from cBio-
Portal (40,41) and analyzed as described below.
Statistical Analysis
Unpaired two-tailed Student’s t test, Mann-Whitney’s test, 
one-way analysis of variance (ANOVA) with Tukey’s post hoc 
test (for multiple comparisons), multiple t test using the Holm-
Sidak method, and Pearson correlation were performed using 
GraphPad Prism (GraphPad Software, San Diego, CA, www.
graphpad.com). Two-sided log-rank test was performed using 
SPSS Statistics (IBM). Data were presented as mean ± standard 
deviation. Survival curves were estimated based on the Kaplan-
Meier method and compared using log-rank test. P values were 
calculated using two-sided tests. P values of less than .05 were 
considered statistically significant.
Results
Actomyosin Contractility and Reactive Oxygen Species
The actomyosin cytoskeleton favors fast migration in vivo. 
Therefore, we wanted to understand how cells with lowered acto-
myosin contractility adapt to cytoskeletal changes. Rac is crucial 
for the NADPH oxidase complex that generates H2O2 (42). Through 
aquaporins (43,44) or passive diffusion (45,46), H2O2 gets internal-
ized, generating oxidative stress (47). We previously described 
how decreasing actomyosin contractility increased Rac1 activ-
ity after one to two hours of treatment (8). Using longer treat-
ments, we found that Rac1 activation is sustained for 24 hours (P 
= .037) after ROCK inhibitor treatment (Figure 1A). We compared 
rounded-contractile A375M2 melanoma cells with more elon-
gated ROCK-inhibited A375M2 cells (treated with H1152, Y27632, 
or Fasudil for 24 hours) (P = .0047, P < .001, P < .001) or with intrin-
sically less contractile A375P cells, with higher Rac1 activity (7,8) 
(Figure 1, B and C). We observed an increase in ROS in all condi-
tions leading to lower contractility. These results were confirmed 
using blebbistatin, ROCK inhibitor GSK269962, or RNAi against 
ROCK1/2 (P = .023) (Figure 1, B and C, lower panels). Furthermore, 
after ROCK inhibition the increase in ROS levels was dependent 
on Rac1 (Supplementary Figure 1A, available online).
The inter-relationship between ROS is shown in 
Supplementary Figure 1B (available online). The addition of H2O2 
to A375M2 cells resulted in increased intracellular ROS (P = .0075) 
(Figure 1D, left) and loss of cell rounding using different types of 
collagen I (P = .033) (Figure 1D, top right panel and bottom panels). 
These morphological changes were associated with decreased 
p-MLC2 (Figure  1E), increased Rac1-GTP (Supplementary 
Figure  1C, available online), and decreased 3D migration (P < 
.001) (Figure 1F). Conversely, the addition of ROS scavengers to 
A375P cells resulted in increased percentage of rounded cells in 
different types of collagen (Figure 1G; Supplementary Figure 1, 
D and E, available online). We could also measure an increase 
in p-MLC2 (12) (Figure  1H; Supplementary Figure  1, F and G, 
available online), increased blebbing (Supplementary Figure 1G, 
available online), and increased 3D migration (Figure 1I). These 
data show an inverse association between oxidative stress and 
“amoeboid” invasion.
Actomyosin Contractility and DNA Damage
We previously performed microarray analysis for gene expres-
sion changes positively associated with actomyosin contractil-
ity (11), where contractility of A375M2 cells was lowered with 
two ROCK inhibitors (H1152 or Y27632) or blebbistatin. We re-
analyzed this gene dataset using Gene Set Enrichment Analysis 
(GSEA) and focused on upregulated genes that are enriched in 
low contractile cells. We found upregulation of genes involved 
in ROS metabolism and DNA damage responses (Supplementary 
Figure 2A and Supplementary Table 1, available online). We found 
similar transcriptional responses comparing A375M2 cells with 
A375P, intrinsically less contractile (8,11,48) (Supplementary 
Table 2, available online).
Following ROS generation, DNA damage causes ATM 
autophosphorylation, which phosphorylates p53 and protects it 
from degradation (21,49,50). After ROCK inhibition using H1152, 
we could detect p-ATM (P = .041, 24 hours) and p-p53 increases 
(P = .02, 24 hours) (Figure  2A; Supplementary Figure  2B, avail-
able online), resulting in p53 stabilization. The same results 
were observed comparing high-contractile A375M2 with low-
contractile A375P (Figure 2A; Supplementary Figure 2C, available 
online). Other ROCK inhibitors (Y27632, Fasudil, and GSK269962) 
and blebbistatin also stabilized p53 protein (Figure  2B; 
Supplementary Figure 2D, available online). ATM promotes H2AX 
phosphorylation (γ-H2AX), which can be detected in DNA Repair 
foci (51). We could measure increased p-H2AX in the nucleus (P 
< .0001 all doses) (Figure 2C top panel; Supplementary Figure 2E, 
available online) and increased 8-hydroxy-2’- deoxyguanosine 
(8-oxodG) staining (P < .0001 all doses) (Figure 2C bottom panel; 
Supplementary Figure 2F, available online).
We selected genes that were upregulated as a result of 
ROS-induced DNA damage and are associated with lower acto-
myosin levels. We found an upregulation of genes involved in 
ROS production—TP53I3 (PIG3), TP53, NOX1, XDH, and NQO2 
(Figure  2D)—and ROS detoxification—GPX and PRDX—indicat-
ing that cells are sensing/responding to oxidative stress. Some 
genes have DNA binding activity as a result of DNA damage—
DDB1/2, OGG1, FANCG, and TP53I3 (PIG3). Importantly, p53 and 
PIG3 were involved both in DNA damage and ROS and were 
inversely associated with actomyosin contractility (Figure  2D). 
PIG3 is a component of the DNA damage response pathway 
that recruits DNA repair machinery to DNA breaks (52) but also 
harbours oxido-reductase activity (53). We therefore focused on 
studying p53-PIG3 and its relationship with actomyosin.
Similar to p53, PIG3 was induced after ROCK inhibition 
(Supplementary Figure 2G, available online). We used a panel of 
melanoma cells with varying degrees of rounding (11) and wild-
type p53. Lowering actomyosin contractility using ROCK inhibi-
tor or via RNAi resulted in loss of cell rounding and increased 
p53 and PIG3 levels (Figure  2E). Similar results were obtained 
with ROCK inhibitor Y27632 (Supplementary Figure  2H, avail-
able online). Rac1 depletion rescued the p53-PIG3 increase after 
lowering actomyosin contractility (Figure  2F). These results 
show that p53-PIG3 expression is dependent on Rac1. This indi-
cates that low actomyosin contractility promotes gene expres-
sion programs involved in ROS metabolism and DNA damage 
response.
3D Migration and PIG3 in Melanoma
We then depleted PIG3 in several melanoma cell lines using dif-
ferent RNAi (Figure 3, A-C; Supplementary Figure 3A, available 
online). Depletion of PIG3 resulted in increased p-MLC2 using 
 at K
ing's College London - Journals D
ept on A
pril 1, 2016
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
4 of 14 | JNCI J Natl Cancer Inst, 2016, Vol. 108, No. 1
a
r
t
ic
le
Figure 1. Actomyosin contractility and oxidative stress. A) A375M2 cells were treated with 5 μM H1152 for different times from one hour to 24 hours, and Rac1 activation 
was assessed by pulldown. Representative immunoblot (top) and quantification (bottom) of Rac1-GTP in pulldown samples and of total Rac1 in total lysate (n = 6, error 
bars are ±SD, two-sided Student’s t test was used to generate P values, *P < .05, **P < .01). B) ROS measurement of A375M2, ROCK-inhibited A375M2 (H1152, 5 μM, Y27632, 
10 μM, Fasudil, 10 μM, and GSK269962, 1 μM), A375P cells, contractility-inhibited A375M2 (blebbistatin, 20 μM), and ROCK1/2-depleted A375M2 cells after incubation with 
DCFH-DA (20 μM). Values are represented as relative mean fluorescence (n = 5, error bars are ±SD, two-sided Student’s t test was used to generate P values, *P < .05, **P 
< .01, ***P < .001). C) Representative immunoblots of myosin light chain II phosphorylation (p-MLC2) levels of cells (n = 5). D) ROS measurement of A375M2 cells treated 
with 10 μM H2O2 for 24 hours is shown in the top left panel. CTR = control (n = 5, error bars are ±SD, two-sided Student’s t test was used to generate P values, **P < .01). 
Top right panel: representative bright-field images of A375M2 cells on top of atelopeptide bovine and telopeptide-intact rat tail collagen I incubated with 10 μM H2O2 for 
24 hours. Scale bar = 20 μm. Bottom left panel: cell morphology A375M2 cells on top of atelopeptide bovine collagen I treated with increasing concentrations of H2O2 for 
24 hours (n = 6, error bars are ±SD, two-sided one-way analysis of variance (ANOVA) with Tukey´s post hoc test was used to generate P values, **P < .01, ***P < .001). Bottom 
right panel: cell morphology A375M2 cells on telopeptide-intact collagen I incubated with 10 μM H2O2 for 24 hours (n = 3, error bars are ±SD, two-sided Student’s t test 
was used to generate P values, *P < .05). E) Representative immunoblot (top) and quantification (bottom) of MLC2 phosphorylation after treatment with increasing con-
centrations of H2O2 for 24 hours (n = 7, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, *P < .5, **P < .01, ***P < .001). 
F) 3D migration into telopeptide-intact rat tail collagen I of A375M2 cells after stimulation with 10 μM H2O2 (n = 5, error bars are ±SD, two-sided Student’s t test was used 
to generate P values, ***P < .001. G) Cell morphology of A375P cells treated with the ROS scavengers N-acetyl cysteine, mannitol, sodium azide, tiron, and sodium pyruvate 
for 24 hours on top of telopeptide-intact rat tail collagen I (n = 3, error bars are ±SD, two-sided Student’s t test was used to generate P values, ***P < .001, ****P < .0001). 
H) Quantification of p-MLC2 fluorescence signal relative to the cell area of confocal images in A375P cells after incubation with the ROS inhibitors N-acetyl cysteine, man-
nitol, sodium azide, tiron, and sodium pyruvate on telopeptide-intact rat tail collagen I. Dots represent single cells from three independent experiments, and values are 
normalized to the cell area (n = 3 experiments; N = 90 cells, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, ****P 
< .0001). I) 3D migration into telopeptide-intact rat tail collagen I of A375P cells treated with ROS scavengers N-acetyl cysteine, mannitol, sodium azide, tiron, and sodium 
pyruvate (n = 6, error bars are ±SD, two-sided Student’s t test was used to generate P values, **P < .01). See also Supplementary Figure 1 (available online).
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Figure 2. Actomyosin contractility and DNA damage. A) Immunoblots for p-ATM, p-p53 (S15), p53, and p-MLC2 of A375M2 and A375P cells treated with ROCK inhibitor 
H1152 (5 μM) for the indicated time points (n = 5, representative blots are shown). B) Immunoblots for p53 and p-MLC2 levels of A375M2 cells treated with ROCK inhibi-
tors H1152 (5 μM), Y27632 (10 μM), Fasudil (10 μM), and actomyosin inhibitor blebbistatin (20 μM) and ROCK inhibitor GSK269962 (1 μM) (n = 5, representative blots are 
shown). C) Top panel: representative confocal images (top) of γ-H2AX (green) immunostaining in A375M2 cells treated with ROCK inhibitor H1152. DAPI was used to 
stain DNA (blue). Scale bar = 10 μm. Quantification of the nuclear levels in arbitrary units (a.u.) of γ-H2AX in A375M2 upon ROCK inhibition (H1152) from three inde-
pendent experiments is shown below (n = 3 experiments; N = 150 nuclei, error bars are ±SD, two-sided one-way analysis of variance (ANOVA) with Tukey’s post hoc test 
was used to generate P values, ****P < .0001). Bottom panel: representative confocal images (top) of 8-oxodG (green) immunostaining in A375M2 cells treated with ROCK 
inhibitor H1152. DAPI was used to stain DNA (blue). Scale bar = 10 μm. Quantification of the nuclear levels in arbitrary units (a.u.) of 8-oxodG in A375M2 upon ROCK 
inhibition (H1152) from three independent experiments is shown below (n = 3 experiments; N = 150 nuclei, error bars are ±SD, two-sided one-way ANOVA with Tukey’s 
post hoc test was used to generate P values, ****P < .0001). D) Heat map of ROS-regulating gene expression following inhibition of actomyosin contractility in A375M2 
cells—conditions shown are A375M2 cells, A375P cells, A375M2 cells treated with blebbistatin, H1152, or Y27632. Blue indicates under expression, red overexpression, 
and intensity of color indicates relative change. Rows were colored using a z-score derived from a gene’s expression across all samples (row z-score). A table indicating 
the involvement of these genes in ROS metabolism and/or DNA damage is shown on the right. E) Representative immunoblots (top) and quantification (bottom) of p53 
and PIG3 levels in human wild-type TP53 melanoma Skmel23 (n = 5), A375P (n = 10), WM266.4 (n = 5), SBCL2 (n = 5), WM1361 (n = 13), and A375M2 cells after treatment 
with ROCK inhibitor H1152 (5 μM) for 24 hours (n = 10) or after abrogation of ROCK1 and ROCK2 with siRNA for 72 hours (n = 7) in A375M2 cells (error bars are ±SD, 
two-sided Student’s t test was used to generate P values, *P < .05, **P < .01, ***P < .001). F) Representative immunoblots for p53, PIG3, p-MLC2, and Rac1 of A375M2 cells 
after depletion of Rac1 for 72 hours and ROCK inhibition treatment with Y27632 (10 μM) for 24 hours (n = 4). See also Supplementary Table 1 and 2 and Supplementary 
Figure 2 (available online).
 at K
ing's College London - Journals D
ept on A
pril 1, 2016
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
6 of 14 | JNCI J Natl Cancer Inst, 2016, Vol. 108, No. 1
a
r
t
ic
le
Figure 3. 3D migration and PIG3 in melanoma. A) Representative confocal images of p-MLC2 (Ser19) and F-actin immunostaining in PIG3-depleted WM1361, SBCL2, and 
A375P cells on atelopeptide bovine collagen I. Scale bar = 20 μm. Inset shows cell blebbing in PIG3-depleted cells (n = 3, representative blots are shown). B) Quantification 
of p-MLC2 immunofluorescence (IF) signal relative to the cell area of confocal images in PIG3-abrogated melanoma cells WM1361, SBCL2, and A375P. Each dot represents 
a single cell from three independent experiments (n = 3 experiments; N = 105 cells, error bars are ±SD, two-sided one-way analysis of variance (ANOVA) with Tukey’s 
post hoc test was used to generate P values, *P < .05, ***P < .001, ****P < .0001). Immunoblots for p-MLC2 levels in PIG3-ablated WM1361, SBCL2, and A375P cells seeded on 
collagen I are shown on the right. Percentage of PIG3 knockdown (KD) is shown below. C) Cell morphology of WM1361, SBCL2, and A375P cells on atelopeptide bovine 
collagen I after PIG3 depletion. Two individual On Target (OT) siRNA oligonucleotides were transfected to deplete PIG3 expression (#1 and #2). PIG3 knockdown (KD) lev-
els are shown below as % (n = 3 in WM1361 and SBCL2 and n = 4 in A375P, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate 
P values, *P < .05, **P < .01). D) Left panel: cell morphology of A375P cells overexpressing empty vector or RNAi resistant PIG3 after PIG3 knockdown (n = 3, error bars are 
±SD, two-sided Student’s t test was used to generate P values, **P < .01). Representative immunoblots for PIG3 and p-MLC2 levels are shown on the right panel (n = 3, 
representative blots are shown). E) Cell morphology of A375P cells stably transfected with shRNA for PIG3 and seeded on atelopeptide bovine and telopeptide-intact 
rat tail collagen I (n = 3, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, ***P < .001, ****P < .0001). Percentage of 
PIG3 knockdown (KD) is shown above. F) Representative immunoblots of p-MLC2 and PIG3 levels of A375P cells on atelopeptide bovine collagen I matrix after shRNA 
depletion of PIG3 (n = 3, a representative experiment is shown). Ctr stands for control. G) 3D migration into atelopeptide bovine and telopeptide-intact rat tail collagen 
I of A375P cells after PIG3 depletion with shRNA (n = 5, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, *P < 
.05). Percentage of PIG3 knockdown (KD) is shown above. H) Random migration of PIG3-depleted A375P cells on telopeptide-intact collagen I (n = 3 experiments; N = 30 
cells, error bars are ±SD, two-sided Student’s t test was used to generate P values, ****P < .0001). See also Supplementary Figure 3 and Supplementary Movies 1 and 2 
(available online).
 at K
ing's College London - Journals D
ept on A
pril 1, 2016
http://jnci.oxfordjournals.org/
D
ow
nloaded from
 
C. Herraiz et al. | 7 of 14
a
r
t
ic
le
immunofluorescence (Figure 3, A and B, top panel) and immu-
noblot (Figure 3B, bottom panel) and increased percent rounded 
cells (Figure  3C; Supplementary Figure  3, A and B, available 
online). Similar results were observed after p53 depletion, which 
resulted in PIG3 downregulation (Supplementary Figure 3, C and 
D, available online). Overexpression of RNAi-resistant PIG3 res-
cued these effects (P = .003) (Figure 3D; Supplementary Figure 3E, 
available online).
We generated stable cell lines using two shRNAs against 
PIG3. Reducing PIG3 in A375P cells resulted in increased percent 
rounded cells (Figure 3E; Supplementary Movies 1 and 2, avail-
able online), increased p-MLC2 levels (Figure 3F; Supplementary 
Figure  3F, available online), and increased 3D-migration 
(Figure  3G). Moreover, cell movement analysis showed that 
A375P cells using amoeboid migration after PIG3 depletion were 
statistically significantly faster than A375P cells using elongated 
migration (P < .0001) (Figure 3H). These results show that loss 
of PIG3 as a result of loss of p53 function favors increased fast 
rounded-amoeboid behavior.
PIG3 Catalytic Activity and the Actomyosin 
Cytoskeleton
PIG3 participates in DNA damage responses in the nucleus and 
produces ROS in the cytoplasm. We explored if the latter func-
tion could impact actomyosin contractility. After ROCK inhi-
bition, increased ROS levels were abolished if PIG3 had been 
depleted from A375M2 cells (Figure 4A). Morphological changes 
induced by ROCK inhibition (H1152, Y27632) were partially res-
cued if PIG3 was ablated (P < .0001) (Figure 4, B and C).
PIG3 oxido-reductase activity needs NADP (53). PIG3 S151V 
is unable to bind NADP and produce ROS (53). PIG3 WT overex-
pression reduced cell rounding (P < .0001) (Figure 4, D and E) and 
p-MLC2 (P = .001) in A375M2 cells (Figure 4, F and G) by increas-
ing ROS (P = .003) (Figure  4H). In contrast, mutant PIG3 S151V 
could not increase ROS and could not suppress amoeboid fea-
tures (Figure 4, D-H).
PIG3 has been involved in cooperative apoptotic responses 
(54), but overexpressing PIG3 WT or S151V did not induce apop-
tosis in A375M2 cells (Supplementary Figure 4, available online) 
compared with adriamycin. These results show that the catalytic 
activity of PIG3 opposes actomyosin without inducing apoptosis.
Regulation of Cytoskeletal Dynamics via PIG3 and 
ARHGAP5/P190RhoB
GTPase activating proteins (GAPs) are negative regulators of 
Rho GTPases (55), and generation of ROS can activate p190Rho-
GAP family and downregulate Rho (56). Depletion of p190Rho-
GAP (p190A) in A375M2 cells did not affect cell morphology 
(Supplementary Figure 5A, available online). Depletion of p190B 
(ARHGAP5) (57) rescued morphological changes (P = .002) and 
p-MLC2 changes (P < .0001) after H2O2 addition (Figure  5, A-C; 
Supplementary Figure  5B, available online). Depletion of 
ARHGAP5 in A375P and WM1361 cells yielded similar results 
(Supplementary Figure 5, C-E, available online). Overexpression 
of Flag-ARHGAP5 in 293T cells treated with H2O2 for four hours 
and 24 hours resulted in reduced Rho activity levels (P = .043 at 4 
hours, P = .042 at 24 hours) (Figure 5D). Therefore, the GAP activ-
ity of ARHGAP5 is stimulated after an increase in ROS.
Overexpression of PIG3 did not alter cell morphology and 
actomyosin levels if cells had been depleted from ARHGAP5 
(Figure  5, E and F; Supplementary Figure  5, F and G, available 
online). PIG3 overexpression resulted in decreased levels of 
active RhoA (P < .001) (Figure 5, G and H), but a recovery of Rho 
activity (P = .013) and p-MLC2 levels (P = .003) was measured 
after ARHGAP5 depletion (Figure 5, G-I). These results show that 
PIG3-dependent oxidative stress activates ARHGAP5 to decrease 
Rho-ROCK-MLC2 signaling. An inverse relationship between 
actomyosin and oxidative stress–induced DNA damage is estab-
lished, short term via regulation of GTPase activity and long 
term via transcriptional changes. Cells repairing oxidative stress 
driven DNA damage will activate p53-PIG3 and ARHGAP5 to sup-
press actomyosin contractility–driven migration (Figure 6).
PIG3 and Cancer Motility In Vivo
We next used two-photon intravital imaging to examine the 
movement of cells in A375M2 xenografts. We generated GFP-
stable cell lines where PIG3 was overexpressed (Supplementary 
Figure  6, A-D, and Supplementary Movies 3 and 4, available 
online). When tumors reached the same size, imaging showed 
that tumor cell motility was reduced in PIG3-overexpressing 
cells compared with control cells (P = .011) (Figure 7, A and B; 
Supplementary Movies 5 and 6, available online). Figure  7A 
shows merged red, green, and blue images taken from three dif-
ferent time points 630 s apart in the time-lapse movies: spatial 
separation of colors indicates movement, whereas cells that do 
not migrate appear white (17). In A375M2 tumors, cell move-
ment at the periphery is predominantly rounded, “amoeboid” 
movement (8,11,14,17). Melanoma cells can move as single cells 
or follow the same path (58). Cells following the same paths are 
using multicellular “streaming” as a mode of motility, whereas 
cells in isolation are using single-cell motility (58). The reduc-
tion in motility of PIG3-overexpressing cells was associated with 
reduced levels of rounded- “amoeboid” movement and “stream-
ing amoeboid” movement (P = .0016, P = .023, respectively) 
(Figure  7B; Supplementary Figure  6E, available online). These 
data show that PIG3 suppresses “amoeboid” migration both in 
vitro and in vivo.
We confirmed that PIG3-overexpressing cells gave rise 
to tumors with increased expression of PIG3, as meas-
ured by immunohistochemistry (IHC) (P < .001) (Figure  7C; 
Supplementary Figure  6F, available online) and that were 
associated with decreased cell rounding (P < .0001) (Figure 7C, 
right panel). Such PIG3-overexpressing tumors grew slower 
than controls (P = .0397, day 23) (Figure 7D), and mice survived 
longer (median survival, days: A375M2 control: 33.5; A375M2-
PIG3: 37.0; P = .046) (Figure 7E). These results indicate that PIG3 
re-expression in melanoma cells suppresses fast amoeboid 
movement.
Actomyosin Contractility and PIG3 in Human 
Melanomas
We used the publicly available database TCGA (http://cancerge-
nome.nih.gov/) and found that PIG3 levels were decreased in 
metastatic lesions (P < .001), while the actomyosin regulators 
ROCK1 and ROCK2 were increased (P < .0001 ROCK1, P < .001 
ROCK2) (n = 354) (Figure 8, A and B; Supplementary Figure 7A, 
available online). There was a negative correlation between 
PIG3 and ROCK1/2 levels (r  =  -0.2261, P < .0001 ROCK1 vs 
PIG3, r  =  -0.1381 P = .0093 ROCK2 vs PIG3) (Figure  8, C and D; 
Supplementary Figure 7B, available online) and a positive cor-
relation between ROCK1 and ROCK2 (P < .0001) (Figure  8E; 
Supplementary Figure 7B, available online).
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We then used IHC in tissue microarrays (TMAs) (n = 164 mela-
noma patients) to associate PIG3 expression with morphological 
features. Each sample was scored blind for intensity as nega-
tive (0), low (1), moderate (2), or high (3) (Figure 8F). Fifty percent 
of human melanoma patients had lost PIG3 protein expression, 
while 30% had low expression and 3% retained high PIG3 expres-
sion (P < .0001) (Figure 8F). PIG3 levels were negatively associated 
with cell rounding in human melanomas (P < .0001) (Figure 8G). 
Figure 4. PIG3 catalytic activity and the actomyosin cytoskeleton. A) ROS measurements of A375M2 treated with ROCK inhibitor Y27632 (10 μM) for 24 hours after 
depletion of PIG3 by siRNA. Values are represented as relative mean fluorescence (n = 3, error bars are ±SD, two-sided one-way analysis of variance (ANOVA) with 
Tukey’s post hoc test was used to generate P values, **P < .01). B) Representative bright-field images of PIG3-depleted–A375M2 cells on bovine collagen I and incubated 
with ROCK inhibitors H1152 (5 μM) or Y27632 (10 μM) for 24 hours. Scale bar = 20 μM. C) Cell morphology of A375M2 cells on top of bovine collagen I after PIG3 deple-
tion prior to treatment with H1152 (5 μM) or Y27632 (10 μM) for 24 hours (n = 3, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to 
generate P values, ***P < .001, ****P < .0001). Percentage of PIG3 knockdown is shown below. D) Representative confocal images of PIG3 (green) immunostaining in A375M2 
cells transiently transfected with empty vector pcDNA3 or with the constructs HA-PIG3 WT or HA-PIG3 S151V on bovine collagen I. F-actin was also stained (red). 
Scale bar = 20 μm. E) Cell morphology of A375M2 cells overexpressing HA-PIG3 WT or HA-PIG3 S151V on bovine collagen I matrix (n = 4, error bars are ±SD, two-sided 
one-way ANOVA with Tukey’s post hoc test was used to generate P values, ****P < .0001). F) Representative immunoblots for p-MLC2 and PIG3 protein levels in PIG3-
overexpressing A375M2 cells (n = 3, representative blots are shown). G) Quantification of MLC2 phosphorylation levels normalized to cells transfected with the empty 
vector (n = 3, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, **P < .01). H) ROS measurement of A375M2 cells 
transfected with empty vector pcDNA3, PIG3 WT, or S151V PIG3. ROS levels were represented as relative mean fluorescence (n = 4, error bars are ±SD, two-sided one-way 
ANOVA with Tukey’s post hoc test was used to generate P values, *P < .05, **P < .001). See also Supplementary Figure 4 (available online).
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Figure 5. Regulation of cytoskeletal dynamics via PIG3 and ARHGAP5/P190RhoB. A) Representative bright-field images seeded on atelopeptide bovine collagen I and 72 
hours post-transfection, treated with H2O2 (10 μM) for 24 hours. Scale bar = 20 μm. B) Cell morphology of ARHGAP5-depleted A375M2 cells on top of atelopeptide col-
lagen I compared with telopeptide-intact rat tail collagen I after stimulation with 10 μM H2O2 (n = 3, error bars are ±SD, two-sided one-way analysis of variance (ANOVA) 
with Tukey’s post hoc test was used to generate P values, **P < .01, ***P < .001). Immunoblot for ARHGAP5 is shown below. NS = nonsignificant. C) Representative confocal 
images (left) of p-MLC2 (green) immunofluorescence (IF) and quantification of p-MLC2 (Ser19) levels (right) of ARHGAP5-ablated A375M2 cells stimulated with H2O2 
(10 μM) for 24 hours. F-actin was also stained (red). Each dot represents a single cell; values are relative to the cell area and represented in arbitrary units (a.u.) from 
three independent experiments (n = 3 experiments; N = 90 cells, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, 
*P < .05, ***P < .001, ****P < .0001). Scale bar = 20 μm. D) Representative immunoblots (top) and quantification (bottom) showing Myc-RhoA activation and Flag-ARHGAP5 
overexpression in HEK293T cells treated with 10 μM H2O2 (n = 3, error bars are ±SD, two-sided Student’s t test was used to generate P values, *P < .05). E) Cell morphol-
ogy of PIG3-overexpressing A375M2 cells after stimulation with 10 μM H2O2 (n = 3, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to 
generate P values, ****P < .0001). F) Quantification of p-MLC2 (Ser19) levels from confocal images of p-MLC2 immunofluorescence (IF) stainings of PIG3-overexpressing 
A375M2 cells stimulated with H2O2 (10 μM) for 24 hours. Each dot represents a single cell, and values are represented in arbitrary units (a.u.) from three independent 
experiments. NS = nonsignificant (n = 3 experiments; N = 90 cells, error bars are ±SD, two-sided one-way ANOVA with Tukey’s post hoc test was used to generate P values, 
****P < .0001). G) Representative immunoblots showing RhoA activation, ARHGAP5, PIG3, and p-MLC2 levels in A375M2 cells overexpressing PIG3 WT after knocking 
down ARHGAP5 (n = 4, a representative blot is shown). H) Quantification of Rho-GTP normalized to total Rho levels in PIG3-overexpressing A375M2 cells after depleting 
ARHGAP5 (n = 4, error bars are ±SD, two-sided Student’s t test was used to generate P values, *P < .05). I) Quantification of MLC2 phosphorylation levels from (G) (n = 4, 
error bars are ±SD, two-sided Student’s t test was used to generate P values, *P < .05, **P < .01). See also Supplementary Figure 5 (available online).
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These results show that the suppressive mechanism that PIG3 
exerts on invasive behavior is frequently lost in melanomas and 
it associates with a gain in actomyosin (Figure 8H).
Discussion
We described an inverse balance between actomyosin contrac-
tility and oxidative stress-induced DNA damage (Figure  6 and 
Figure  8H). These results suggest that antioxidants will favor 
actomyosin contractility and invasive behavior. Importantly, 
the subsequent DNA damage response will suppress the acto-
myosin machinery to impair migration of DNA-damaged cells. 
Melanoma cells have a fine-tuned internal sensor regulating the 
balance between DNA damage/DNA repair and actomyosin con-
tractility, which will determine if cancer cells will spread.
In melanoma, p53 mutations are less frequent than in other 
skin cancers (59–62), but functional attenuation is needed for 
melanoma development (63). New approaches to reactivate p53 
for melanoma therapy are needed (64,65). We find enhanced p53 
when actomyosin contractility is lowered. RhoC is a key regu-
lator of melanoma metastasis (48), and high actomyosin levels 
driven by Rho-ROCK activity could impair some p53 functions in 
late stages of melanoma. In line with this, we found an inverse 
correlation between ROCK1/2 and PIG3 levels in melanoma.
Interestingly, we found that PIG3 expression is positively 
regulated by Rac1-induced ROS production via p53 stabilization 
(Figure 2F). We describe an alternative mechanism by which Rac1 
suppresses actomyosin contractility via transcriptional regula-
tion of PIG3. In the long term, PIG3 upregulation could be support-
ing and sustaining ROS production. Upon lowering actomyosin 
contractility, we observed an upregulation of other genes that 
could be increasing ROS in the long term, such as NOX1 and XDH. 
In the short term, Rac1 generation of ROS—via p67phox—could 
directly activate ARHGAP5 and suppress Rho activity. These two 
mechanisms are superimposed over time and responsible for the 
short- and long-term suppression of the actomyosin machinery 
by Rac1-induced oxidative stress (Figure 6).
PIG3 was discovered with 12 other proteins induced by p53 
before apoptosis onset; however, none of these genes was suf-
ficient to induce apoptosis on its own (54). PIG3 has also been 
reported to recruit Rad50, Mre11, 53BP1, and Nbs1 to sites of DNA 
break lesions (66). We found that cytoplasmic PIG3 has an impor-
tant additional and unexpected role in impairing migration of cells 
that are repairing DNA. It would be interesting to establish if other 
components of the DNA repair machinery that are upregulated in 
our study could be relevant in controlling tumor dissemination.
PIG3 expression is regulated through its promoter (67) and 
is found in most vertebrates, plants, protists, and bacteria, but 
has not been found in rodents (53). Therefore, melanoma mouse 
models studying p53 function (63,68–70) may have missed the 
role of PIG3. In this study, we found that high levels of PIG3 
impair tumor invasion by suppressing actomyosin contractil-
ity. This reinforces the value of ROCK inhibition to reactivate 
p53-PIG3 as we observed that combining chemotherapeutics 
Figure 6. Balance between Rho-ROCK and oxidative stress–induced DNA damage. Oxidative stress–dependent DNA damage results in p53 stabilization in cells with 
low actomyosin contractility. In turn, p53 drives the expression of several genes involved in oxidative stress metabolism and DNA damage responses, including PIG3. 
PIG3, apart from its DNA damage response functions, sustains production of ROS to inhibit cytoskeletal Rho-ROCK signaling through ARHGAP5, suppressing rounded-
amoeboid fast tumor dissemination.
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Figure 7. PIG3 and cancer motility in vivo. A) Multiphoton intravital microscopy of A375M2 subcutaneous tumors (GFP) and representative images of control (top) and PIG3 
WT (bottom) stably transfected cells. Right panels show at higher magnification motion analysis of areas indicated in yellow, red, green, and blue images from three time 
points 630s apart are overlaid, and distinct areas of color indicate motile cells. Scale bar = 50 μm. B) Quantification of the number of motile cells in control and in PIG3 
WT–overexpressing A375M2 cells (7 fields/mouse; 7 mice/condition, error bars are ±SD, two-sided Student’s t test was used to generate P values). C) Representative images 
of mouse xenografts sections of pcDNA3 or PIG3 WT–overexpressing A375M2 stained for PIG3 or for hematoxylin and eosin (H&E). Scale bar = 50 μm. Graph representing 
PIG3 expression levels in the xenografts is shown in the middle (7 mouse xenografts/condition, error bars are ±SD, two-sided Student’s t test was used to generate P values). 
Cell morphology (roundness index) calculated from H&E images of xenografts of mouse tumors of A375M2 control or PIG3 WT–overexpressing cells is shown on the right 
panel (7 mouse xenografts/condition, 6 fields/mouse xenograft, error bars are ±SD, two-sided Student’s t test was used to generate P values). D) Volume of subcutaneous 
tumors at different days after injecting A375M2 or A375M2 cells overexpressing PIG3 WT. The results show mean volumes measured on days 5, 9, 12, 16, 19, and 23 for 
groups of seven mice/condition, with error bars to represent ±SD. A two-sided Student’s t test was used to calculate P value for day 23. E) Survival curves for subcutaneous 
xenograft mouse models of A375M2 control cells and PIG3 WT–overexpressing A375M2 cells. The survival curve represents the percentage of animals alive at the indicated 
time point after injection. (Survival curves were estimated by the Kaplan Meier method and compared among subsets using the log-rank test. Differences with a P value < 
.05 were considered statistically significant, and all tests were two-sided). See also Supplementary Figure 6 and Supplementary Movies 3–6 (available online).
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Figure 8. Actomyosin contractility and PIG3 in human melanomas. A) PIG3 expression in primary and metastasis melanoma human tissues using normalized 
mRNA expression data from The Cancer Genome Atlas (TCGA) database. B) ROCK1 and ROCK2 expression in primary and metastasis melanoma human tissues 
using normalized mRNA expression data from TCGA database. A and B) Box plots show the median, quartiles, 10% and 90% values and outliers (Mann-Whitney test 
was used to generate P values). C-E) Scatter plot of PIG3, ROCK1, and ROCK2 expression correlation analysis (Pearson’s r) using normalized mRNA expression data 
from TCGA database. C and D) Results showed a significant negative correlation between PIG3 and ROCK1 expression (r = -0.2261) and between PIG3 and ROCK2 
expression (r = -0.1381). E) Analysis revealed a significant positive correlation between ROCK1 and ROCK2 expression (r = 0.7347). F) Number of melanoma patients 
expressing negative, low, moderate, or high levels of PIG3 in the tissue microarrays (TMAs). The number of melanoma patients expressing the different PIG3 levels 
is shown in the graph (Chi-square test was used to generate P values). A representative image of the four grades of staining intensity used to score PIG3 expression 
in the tissue microarray is shown above. Scale bar = 100 μm. G) Association between morphological features (roundness index) and PIG3 staining intensity in two 
melanoma TMAs. Stain intensity was scored as negative or positive (low, moderate, and high level) intensity for PIG3 expression in the TMAs. For cell morphol-
ogy, three random fields per core in the hematoxylin and eosin–stained TMAs were randomly chosen and the roundness index was calculated using ImageJ (30 
cells/core) (error bars are ±SD, two-sided Student’s t test was used to generate P values). H) Diagram representing the relationship between cytoskeletal Rho-ROCK 
signaling, PIG3 catalytic activity resulting in high oxidative stress-dependent DNA damage and its association with less tumor invasion, and thus less metastatic 
potential. See also Supplementary Figure 7 (available online).
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with ROCK inhibition resulted in synergic p53-PIG3 reactiva-
tion (Supplementary Figure 8A, available online). These findings 
could be exploited in the clinic because ROCK inhibitors are well 
tolerated in humans and used for several disorders (71–73).
One limitation of our study was that we did not distinguish 
between different intracellular sources of ROS, such as mito-
chondria, peroxisomes, endoplasmic reticulum, cell mem-
branes, etc. (74). Furthermore, while our study was carried out 
in p53 wild-type melanomas, mutant-p53 cell lines did not regu-
late p53 levels upon ROCK inhibition (Supplementary Figure 8B, 
available online). Mutant p53 displays constitutive p-S15 (75), a 
key residue protecting p53 from degradation; this could explain 
why we cannot detect further stabilization. It will be important 
to determine how DNA repair and tumor migration are inte-
grated in p53-mutant melanomas.
Oncogenic signaling in melanoma leads to the accumulation 
of high ROS leading to senescence (76) that can be prevented by 
antioxidants (77,78). Melanocyte senescence and apoptosis can 
be caused by an imbalance between ROS production and detoxi-
fication (20). It will be important to assess if actomyosin con-
trols senescent and apoptotic responses. PIG3-overexpressing 
cells showed increased enzymatic activity of β-galactosidase 
over time (Supplementary Figure 8C, available online). Because 
PIG3-overexpressing tumors grew more slowly, further work is 
needed to understand if senescence is supported by PIG3.
In the current study, we present an important and intriguing 
example where increased ROS might be beneficial to suppress 
tumor invasion; therefore, the broad use of antioxidants should 
be carefully assessed in melanoma.
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